Effectiveness and safety of recombinant activated factor

Patients with severe and persistent bleeding have high mortality. rFVIIa has been approved for the prophylaxis and treatment of the following types of hemorrhages: in patients with inhibitors of the coagulation, with congenital deficiency of FVII and with Glanzmann thrombasthenia. The aim of the study was to evaluate the role of rFVIIa on blood transfusion requirements and its safety. Recently there have been reports of this use in refractory severe hemorrhage (liver transplantation, trauma patients, upper GI bleeding, intracerebral hemorrhage).